Top Markets
Coin of the day
Climb Bio, Inc. Climb Bio, Inc.

Climb Bio, Inc.

CLYM
Rang in aandelen #10440
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic... Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Aandeelprijs
$14.66
Laatst gesynchroniseerd: 2026-08-28
Marktkapitalisatie
$839.37M
Verandering (1 dag)
-2.67%
Verandering (1 jaar)
557.32%
Land
US
Handel Climb Bio, Inc. (CLYM)

Categorie

Dividendrendementgeschiedenis voor Climb Bio, Inc. (CLYM)
Het dividendrendement (TTM) van Climb Bio, Inc. (aandelsymbool: CLYM) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Climb Bio, Inc. (CLYM) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH